Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Down – Here’s Why

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) gapped down before the market opened on Wednesday . The stock had previously closed at $16.36, but opened at $15.57. Daiichi Sankyo shares last traded at $15.36, with a volume of 5,755 shares trading hands.

Analysts Set New Price Targets

Separately, Zacks Research upgraded shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 5th. One analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy”.

Daiichi Sankyo Stock Performance

The company has a debt-to-equity ratio of 0.18, a current ratio of 2.69 and a quick ratio of 1.85. The firm has a market cap of $29.31 billion, a price-to-earnings ratio of 16.46, a price-to-earnings-growth ratio of 1.17 and a beta of -0.16. The company has a fifty day moving average price of $17.36 and a two-hundred day moving average price of $19.53.

Daiichi Sankyo (OTCMKTS:DSNKY) last announced its quarterly earnings data on Monday, May 11th. The company reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.18). The firm had revenue of $3.76 billion during the quarter, compared to analyst estimates of $3.74 billion. Daiichi Sankyo had a net margin of 12.32% and a return on equity of 15.74%. Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. As a group, equities research analysts expect that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.91 EPS for the current year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.